Payment overview · 2025
General Payments
$104,563.91
289 reported records · 21 companies
Healthcare provider profile · identity verified
Christopher D Bojrab, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CARMEL, IN · NPI 1689659013
Verified facts
What the public records show
CMS Open Payments records show Christopher D Bojrab, M.D. received $104,563.91 in general payments during 2025 across 289 reported records.
Axsome Therapeutics, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Auvelity, Caplyta, Ingrezza, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Vraylar by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Auvelity by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Caplyta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ingrezza by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27,175.74 | 26.0% | 53 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26,022.00 | 24.9% | 59 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18,218.05 | 17.4% | 52 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $12,057.75 | 11.5% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $8,968.48 | 8.6% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $5,790.43 | 5.5% | 22 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $3,445.92 | 3.3% | 15 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $1,050.00 | 1.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $451.03 | 0.4% | 21 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $413.12 | 0.4% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $328.47 | 0.3% | 14 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $157.61 | 0.1% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $109.92 | 0.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.72 | 0.1% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $71.38 | 0.1% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.37 | 0.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $56.85 | 0.1% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.38 | 0.0% | 2 | 2025 |
| Vertical Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $35.96 | 0.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.82 | 0.0% | 1 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $13.91 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,997.00 | 19 |
| Honoraria | $25,114.00 | 15 |
| Consulting Fee | $13,916.25 | 6 |
| Food and Beverage | $6,868.13 | 201 |
| Travel and Lodging | $5,539.03 | 45 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,050.00 | 2 |
| Education | $79.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27,101.16 | 46 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24,502.36 | 55 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18,218.05 | 52 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $8,771.66 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $5,744.64 | 20 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $3,445.92 | 15 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $1,050.00 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $607.05 | 24 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $451.03 | 21 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $413.12 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $328.47 | 14 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $157.61 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $117.32 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $77.72 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $74.58 | 7 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $71.38 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $58.37 | 3 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $56.85 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $45.79 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $45.79 | 2 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $36.38 | 2 | 2025 |
Source payment records
|
|||||
| Relexxii Normalized: relexxii |
Drug | Vertical Pharmaceuticals, LLC | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7.14 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Bupropion Xl | Bupropion Hcl | 249 | 39 |
| Clonazepam | Clonazepam | 245 | 39 |
| Gabapentin | Gabapentin | 226 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 43 |
| Alprazolam | Alprazolam | 172 | 28 |
| Trazodone Hcl | Trazodone Hcl | 151 | 37 |
| Lorazepam | Lorazepam | 117 | 22 |
| Lamotrigine | Lamotrigine | 106 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 23 |
| Mirtazapine | Mirtazapine | 95 | 19 |
| Armodafinil | Armodafinil | 87 | 16 |
| Vilazodone Hcl | Vilazodone Hcl | 83 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 16 |
| Sertraline Hcl | Sertraline Hcl | 76 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 72 | 14 |
| Buspirone Hcl | Buspirone Hcl | 69 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 12 |
| Aripiprazole | Aripiprazole | 68 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 64 | suppressed |
| Topiramate | Topiramate | 62 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Eszopiclone | Eszopiclone | 53 | 13 |
| Vraylar | Cariprazine Hcl | 53 | suppressed |
| Olanzapine | Olanzapine | 52 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 48 | suppressed |
| Alprazolam Er | Alprazolam | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Caplyta | Lumateperone Tosylate | 40 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Ingrezza | Valbenazine Tosylate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 24 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Dayvigo | Lemborexant | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Saphris | Asenapine Maleate | 14 | suppressed |
| Alprazolam Xr | Alprazolam | 13 | suppressed |
| Fluoxetine Dr | Fluoxetine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Nefazodone Hcl | Nefazodone Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Dronabinol | Dronabinol | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104,563.91 · 289 records | Axsome Therapeutics, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, Jornay PM, LYBALVI, NUPLAZID, QULIPTA, REXULTI, Relexxii, SPRAVATO, Sunosi, UBRELVY, UZEDY, VRAYLAR, WELLBUTRIN, XYWAV, Xelstrym, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error